AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings of claims in the application:

Claims 1-22 (cancelled)

Claim 23 (previously presented): A method for the generation of HLA-haploidentical antigenpresenting cells for the treatment of tumor diseases in a patient comprising the following steps:

- providing antigen-presenting cells from a donor which are HLA-haploidentical with respect to those of the patient;
- introducing proteins and/or peptides or RNA or DNA or cDNA encoding said proteins and/or peptides which are overexpressed in tumor cells or are derived from autologous tumor cells into the HLA-haploidentical antigen-presenting cells.

Claim 24 (previously presented): The method according to claim 23 wherein proteins and/or peptides or RNA or DNA or cDNA, respectively, encoding said proteins and/or peptides from several different tumor cell lines are introduced into the HLA-haploidentical antigen-presenting cells.

Claim 25 (previously presented): The method according to claim 23 characterized in that first RNA from tumor cells is reverse transcribed into cDNA, the cDNA is amplified by means of PCR and subsequently the cDNA is transcribed into RNA.

Claim 26 (previously presented): The method according to claim 23 wherein antigen-presenting cells of two different HLA-haploidentical individuals are used.

Claim 27 (currently amended): A pharmaceutical composition—for the treatment of a tumor disease in a patient, comprising antigen-presenting cells into which proteins and/or peptides or RNA or DNA or cDNA encoding said proteins and/or peptides which are overexpressed in tumor cells of a patient with a tumor disease or are derived from autologous tumor cells from the patient have been

Docket No.: 559412000200

introduced, wherein the antigen-presenting cells are HLA-haploidentical with respect to those of the patient.

Claim 28 (previously presented): The pharmaceutical composition according to claim 27, wherein the HLA-haploidentical antigen-presenting cells are characterized in that said proteins and/or peptides or RNA or DNA or cDNA encoding said proteins and/or peptides which are overexpressed in tumor cells or are derived from autologous tumor cells are selected from the following tumor cells: carcinomas, tumor cells of the hematopoietic system, cells of mesenchymal tumors, cells of epithelial tumors, cells of ectodermal tumors, and cells of embryonic tumors from undifferentiated tissue.

Claim 29 (previously presented): The pharmaceutical composition according to claim 27, wherein the HLA-haploidentical antigen-presenting cells contain proteins and/or peptides or RNA or DNA or cDNA encoding said proteins and/or peptides from several different tumor cell lines.

Claim 30 (previously presented): The pharmaceutical composition according to claim 27, wherein the HLA-haploidentical antigen-presenting cells are characterized in that said antigen-presenting cells are dendritic cells or macrophages.

Claim 31 (cancelled)

Claim 32 (previously presented): A composition according to claim 27 characterized in that it is a vaccine.

Claim 33 (previously presented): A method of treatment of tumor diseases in a patient comprising administering to said patient a therapeutically effective amount of HLA-haploidentical antigen-presenting cells into which proteins and/or peptides or RNA or DNA or cDNA encoding said proteins and/or peptides which are overexpressed in tumor cells or are derived from autologous tumor cells have been introduced.

Docket No.: 559412000200

Claim 34 (previously presented): The method according to claim 33 characterized in that said HLA-haploidentical antigen-presenting cells are used for the treatment of tumors comprising: carcinomas, tumors of the hematopoietic system, mesenchymal tumors, epithelial tumors, ectodermal tumors, and embryonic tumors from undifferentiated tissue.

Claim 35 (previously presented): The method according to claim 33 characterized in that HLA-haploidentical antigen-presenting cells of two different HLA-haploidentical individuals are used.

Claim 36 (previously presented): The method according to claim 35 characterized in that RNA is employed which has been reverse transcribed from autologous tumor cells into cDNA, the cDNA has been amplified by means of PCR and subsequently the cDNA has been transcribed into RNA.

Claim 37 (currently amended): The method according to claim [23]]33 characterized in that said HLA-haploidentical antigen-presenting cells are applied by the intravenous, subcutaneous or intramuscular route.

Claim 38 (previously presented): The method of claim 23, wherein, into the HLA-haploidentical antigen-presenting cells, proteins and/or peptides or RNA or DNA or cDNA, respectively, encoding said proteins and/or peptides overexpressed in tumor cells or are derived from autologous tumor cells have been introduced in recombinant form.

Claim 39 (previously presented): The method according to claim 23 characterized in that RNA or DNA or cDNA is introduced into the HLA-haploidentical antigen-presenting cells which encodes tumor-defined antigens, wherein the tumor-defined antigens are antigens overexpressed in the tumor cells.

Claim 40 (previously presented): The method according to claim 23 characterized in that said antigen-presenting cells are dendritic cells or macrophages.

Claim 41 (currently amended): The method of claim [[23]]33, wherein, into the HLA-haploidentical antigen-presenting cells, proteins and/or peptides or RNA or DNA or cDNA

encoding said proteins and/or peptides from several different tumor cell lines have been introduced for the treatment of tumor diseases in said patient.

Claim 42 (previously presented): The method according to claim 41 wherein pooled cRNA from two or three different tumor cell lines is introduced.

Claim 43 (previously presented): The pharmaceutical composition according to claim 28, wherein the carcinomas are selected from the group consisting of ovarian, mammary and renal cell carcinomas, the tumor cells of the hematopoietic system are selected from the group consisting of leukemias and lymphomas, the mesenchymal tumors are sarcomas, the ectodermal tumors are melanomas, and/or the cells of embryonic tumors from undifferentiated tissue are selected from the group consisting of blastomas and teratomas.

Claim 44 (previously presented): The method according to claim 34, wherein the carcinomas are selected from the group consisting of ovarian, mammary and renal cell carcinomas, the tumor cells of the hematopoietic system are selected from the group consisting of leukemias and lymphomas, the mesenchymal tumors are sarcomas, the ectodermal tumors are melanomas, and/or the cells of embryonic tumors from undifferentiated tissue are selected from the group consisting of blastomas and teratomas.

Claim 45 (previously presented): The method according to claim 39, wherein the tumor-defined antigens are selected from the group consisting of oncogenes, proteins providing a growth advantage to the tumor and/or ensuring its survival, cell cycle regulatory proteins, transcription factors, mucins, and proteins involved in the regulation of cell division.

Claim 46 (previously presented): The method according to claim 45, wherein the tumor antigens are HER2/neu, PSMA, WT-1, MUC-1, or telomerase.